 | • レポートコード：GIR-2104Z12288 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、強皮症診断・治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。強皮症診断・治療の種類別市場規模（コルチコステロイド、免疫抑制剤、エンドセリン受容体作動薬、カルシウムチャネル遮断薬、PDE-5阻害薬、キレート剤、プロスタサイクリン類似体、その他（H2遮断薬、プロトンポンプ阻害薬、ACE阻害薬など））、用途別市場規模（皮膚生検、画像技術、血液検査、心電図・心エコー図、呼吸機能検査）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・強皮症診断・治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Actelion Pharmaceuticals, Inc.、Boehringer Ingelheim、Bayer AG、Cytori Therapeutics, Inc.、Cumberland Pharmaceuticals Inc、Gilead Sciences, Inc.、Pfizer, Inc.、Sanofi、Corbus Pharmaceutical Holdings, Inc.、F. Hoffmann La Roche Ltd.、Merck KGaA ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：コルチコステロイド、免疫抑制剤、エンドセリン受容体作動薬、カルシウムチャネル遮断薬、PDE-5阻害薬、キレート剤、プロスタサイクリン類似体、その他（H2遮断薬、プロトンポンプ阻害薬、ACE阻害薬など） ・用途別分析2016年-2026年：皮膚生検、画像技術、血液検査、心電図・心エコー図、呼吸機能検査 ・強皮症診断・治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・強皮症診断・治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・強皮症診断・治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・強皮症診断・治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・強皮症診断・治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Scleroderma Diagnostics and Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Scleroderma Diagnostics and Therapeutics size is estimated to be USD xx million in 2025 from USD xx million in 2019, with a change XX% between 2019 and 2020. The global Scleroderma Diagnostics and Therapeutics market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Scleroderma Diagnostics and Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Corticosteroids
Immunosuppressive Agents
Endothelin Receptor Agonists
Calcium Channel Blockers
PDE-5 Inhibitors
Chelating Agents
Prostacyclin Analogues
Others (H2 Blockers, Proton Pump Inhibitors, ACE Inhibitors etc.)
Market segment by Application, can be divided into
Skin Biopsy
Imaging Techniques
Blood Tests
Electrocardiogram and Echocardiogram
Pulmonary Function Tests
Market segment by players, this report covers
Actelion Pharmaceuticals, Inc.
Boehringer Ingelheim
Bayer AG
Cytori Therapeutics, Inc.
Cumberland Pharmaceuticals Inc
Gilead Sciences, Inc.
Pfizer, Inc.
Sanofi
Corbus Pharmaceutical Holdings, Inc.
F. Hoffmann La Roche Ltd.
Merck KGaA
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Scleroderma Diagnostics and Therapeutics
1.2 Classification of Scleroderma Diagnostics and Therapeutics by Type
1.2.1 Overview: Global Scleroderma Diagnostics and Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Scleroderma Diagnostics and Therapeutics Revenue Market Share by Type in 2020
1.2.3 Corticosteroids
1.2.4 Immunosuppressive Agents
1.2.5 Endothelin Receptor Agonists
1.2.6 Calcium Channel Blockers
1.2.7 PDE-5 Inhibitors
1.2.8 Chelating Agents
1.2.9 Prostacyclin Analogues
1.2.10 Others (H2 Blockers, Proton Pump Inhibitors, ACE Inhibitors etc.)
1.3 Global Scleroderma Diagnostics and Therapeutics Market by Application
1.3.1 Overview: Global Scleroderma Diagnostics and Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Skin Biopsy
1.3.3 Imaging Techniques
1.3.4 Blood Tests
1.3.5 Electrocardiogram and Echocardiogram
1.3.6 Pulmonary Function Tests
1.4 Global Scleroderma Diagnostics and Therapeutics Market Size & Forecast
1.5 Global Scleroderma Diagnostics and Therapeutics Market Size and Forecast by Region
1.5.1 Global Scleroderma Diagnostics and Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Scleroderma Diagnostics and Therapeutics Market Size by Region, (2016-2021)
1.5.3 North America Scleroderma Diagnostics and Therapeutics Market Size and Prospect (2016-2026)
1.5.4 Europe Scleroderma Diagnostics and Therapeutics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Scleroderma Diagnostics and Therapeutics Market Size and Prospect (2016-2026)
1.5.6 South America Scleroderma Diagnostics and Therapeutics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Scleroderma Diagnostics and Therapeutics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Scleroderma Diagnostics and Therapeutics Market Drivers
1.6.2 Scleroderma Diagnostics and Therapeutics Market Restraints
1.6.3 Scleroderma Diagnostics and Therapeutics Trends Analysis
2 Company Profiles
2.1 Actelion Pharmaceuticals, Inc.
2.1.1 Actelion Pharmaceuticals, Inc. Details
2.1.2 Actelion Pharmaceuticals, Inc. Major Business
2.1.3 Actelion Pharmaceuticals, Inc. Scleroderma Diagnostics and Therapeutics Product and Solutions
2.1.4 Actelion Pharmaceuticals, Inc. Scleroderma Diagnostics and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Actelion Pharmaceuticals, Inc. Recent Developments and Future Plans
2.2 Boehringer Ingelheim
2.2.1 Boehringer Ingelheim Details
2.2.2 Boehringer Ingelheim Major Business
2.2.3 Boehringer Ingelheim Scleroderma Diagnostics and Therapeutics Product and Solutions
2.2.4 Boehringer Ingelheim Scleroderma Diagnostics and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Boehringer Ingelheim Recent Developments and Future Plans
2.3 Bayer AG
2.3.1 Bayer AG Details
2.3.2 Bayer AG Major Business
2.3.3 Bayer AG Scleroderma Diagnostics and Therapeutics Product and Solutions
2.3.4 Bayer AG Scleroderma Diagnostics and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Bayer AG Recent Developments and Future Plans
2.4 Cytori Therapeutics, Inc.
2.4.1 Cytori Therapeutics, Inc. Details
2.4.2 Cytori Therapeutics, Inc. Major Business
2.4.3 Cytori Therapeutics, Inc. Scleroderma Diagnostics and Therapeutics Product and Solutions
2.4.4 Cytori Therapeutics, Inc. Scleroderma Diagnostics and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Cytori Therapeutics, Inc. Recent Developments and Future Plans
2.5 Cumberland Pharmaceuticals Inc
2.5.1 Cumberland Pharmaceuticals Inc Details
2.5.2 Cumberland Pharmaceuticals Inc Major Business
2.5.3 Cumberland Pharmaceuticals Inc Scleroderma Diagnostics and Therapeutics Product and Solutions
2.5.4 Cumberland Pharmaceuticals Inc Scleroderma Diagnostics and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Cumberland Pharmaceuticals Inc Recent Developments and Future Plans
2.6 Gilead Sciences, Inc.
2.6.1 Gilead Sciences, Inc. Details
2.6.2 Gilead Sciences, Inc. Major Business
2.6.3 Gilead Sciences, Inc. Scleroderma Diagnostics and Therapeutics Product and Solutions
2.6.4 Gilead Sciences, Inc. Scleroderma Diagnostics and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Gilead Sciences, Inc. Recent Developments and Future Plans
2.7 Pfizer, Inc.
2.7.1 Pfizer, Inc. Details
2.7.2 Pfizer, Inc. Major Business
2.7.3 Pfizer, Inc. Scleroderma Diagnostics and Therapeutics Product and Solutions
2.7.4 Pfizer, Inc. Scleroderma Diagnostics and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Pfizer, Inc. Recent Developments and Future Plans
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Scleroderma Diagnostics and Therapeutics Product and Solutions
2.8.4 Sanofi Scleroderma Diagnostics and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Sanofi Recent Developments and Future Plans
2.9 Corbus Pharmaceutical Holdings, Inc.
2.9.1 Corbus Pharmaceutical Holdings, Inc. Details
2.9.2 Corbus Pharmaceutical Holdings, Inc. Major Business
2.9.3 Corbus Pharmaceutical Holdings, Inc. Scleroderma Diagnostics and Therapeutics Product and Solutions
2.9.4 Corbus Pharmaceutical Holdings, Inc. Scleroderma Diagnostics and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Corbus Pharmaceutical Holdings, Inc. Recent Developments and Future Plans
2.10 F. Hoffmann La Roche Ltd.
2.10.1 F. Hoffmann La Roche Ltd. Details
2.10.2 F. Hoffmann La Roche Ltd. Major Business
2.10.3 F. Hoffmann La Roche Ltd. Scleroderma Diagnostics and Therapeutics Product and Solutions
2.10.4 F. Hoffmann La Roche Ltd. Scleroderma Diagnostics and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 F. Hoffmann La Roche Ltd. Recent Developments and Future Plans
2.11 Merck KGaA
2.11.1 Merck KGaA Details
2.11.2 Merck KGaA Major Business
2.11.3 Merck KGaA Scleroderma Diagnostics and Therapeutics Product and Solutions
2.11.4 Merck KGaA Scleroderma Diagnostics and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Merck KGaA Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Scleroderma Diagnostics and Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Scleroderma Diagnostics and Therapeutics Players Market Share
3.2.2 Top 10 Scleroderma Diagnostics and Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 Scleroderma Diagnostics and Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Scleroderma Diagnostics and Therapeutics Revenue and Market Share by Type (2016-2021)
4.2 Global Scleroderma Diagnostics and Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Scleroderma Diagnostics and Therapeutics Revenue Market Share by Application (2016-2021)
5.2 Scleroderma Diagnostics and Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Scleroderma Diagnostics and Therapeutics Revenue by Type (2016-2026)
6.2 North America Scleroderma Diagnostics and Therapeutics Revenue by Application (2016-2026)
6.3 North America Scleroderma Diagnostics and Therapeutics Market Size by Country
6.3.1 North America Scleroderma Diagnostics and Therapeutics Revenue by Country (2016-2026)
6.3.2 United States Scleroderma Diagnostics and Therapeutics Market Size and Forecast (2016-2026)
6.3.3 Canada Scleroderma Diagnostics and Therapeutics Market Size and Forecast (2016-2026)
6.3.4 Mexico Scleroderma Diagnostics and Therapeutics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Scleroderma Diagnostics and Therapeutics Revenue by Type (2016-2026)
7.2 Europe Scleroderma Diagnostics and Therapeutics Revenue by Application (2016-2026)
7.3 Europe Scleroderma Diagnostics and Therapeutics Market Size by Country
7.3.1 Europe Scleroderma Diagnostics and Therapeutics Revenue by Country (2016-2026)
7.3.2 Germany Scleroderma Diagnostics and Therapeutics Market Size and Forecast (2016-2026)
7.3.3 France Scleroderma Diagnostics and Therapeutics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Scleroderma Diagnostics and Therapeutics Market Size and Forecast (2016-2026)
7.3.5 Russia Scleroderma Diagnostics and Therapeutics Market Size and Forecast (2016-2026)
7.3.6 Italy Scleroderma Diagnostics and Therapeutics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Scleroderma Diagnostics and Therapeutics Revenue by Type (2016-2026)
8.2 Asia-Pacific Scleroderma Diagnostics and Therapeutics Revenue by Application (2016-2026)
8.3 Asia-Pacific Scleroderma Diagnostics and Therapeutics Market Size by Region
8.3.1 Asia-Pacific Scleroderma Diagnostics and Therapeutics Revenue by Region (2016-2026)
8.3.2 China Scleroderma Diagnostics and Therapeutics Market Size and Forecast (2016-2026)
8.3.3 Japan Scleroderma Diagnostics and Therapeutics Market Size and Forecast (2016-2026)
8.3.4 South Korea Scleroderma Diagnostics and Therapeutics Market Size and Forecast (2016-2026)
8.3.5 India Scleroderma Diagnostics and Therapeutics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Scleroderma Diagnostics and Therapeutics Market Size and Forecast (2016-2026)
8.3.7 Australia Scleroderma Diagnostics and Therapeutics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Scleroderma Diagnostics and Therapeutics Revenue by Type (2016-2026)
9.2 South America Scleroderma Diagnostics and Therapeutics Revenue by Application (2016-2026)
9.3 South America Scleroderma Diagnostics and Therapeutics Market Size by Country
9.3.1 South America Scleroderma Diagnostics and Therapeutics Revenue by Country (2016-2026)
9.3.2 Brazil Scleroderma Diagnostics and Therapeutics Market Size and Forecast (2016-2026)
9.3.3 Argentina Scleroderma Diagnostics and Therapeutics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Scleroderma Diagnostics and Therapeutics Revenue by Type (2016-2026)
10.2 Middle East & Africa Scleroderma Diagnostics and Therapeutics Revenue by Application (2016-2026)
10.3 Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Size by Country
10.3.1 Middle East & Africa Scleroderma Diagnostics and Therapeutics Revenue by Country (2016-2026)
10.3.2 Turkey Scleroderma Diagnostics and Therapeutics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Scleroderma Diagnostics and Therapeutics Market Size and Forecast (2016-2026)
10.3.4 UAE Scleroderma Diagnostics and Therapeutics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Scleroderma Diagnostics and Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Scleroderma Diagnostics and Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Scleroderma Diagnostics and Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Scleroderma Diagnostics and Therapeutics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Scleroderma Diagnostics and Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. Actelion Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
Table 7. Actelion Pharmaceuticals, Inc. Major Business
Table 8. Actelion Pharmaceuticals, Inc. Scleroderma Diagnostics and Therapeutics Product and Solutions
Table 9. Actelion Pharmaceuticals, Inc. Scleroderma Diagnostics and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors
Table 11. Boehringer Ingelheim Major Business
Table 12. Boehringer Ingelheim Scleroderma Diagnostics and Therapeutics Product and Solutions
Table 13. Boehringer Ingelheim Scleroderma Diagnostics and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Bayer AG Corporate Information, Head Office, and Major Competitors
Table 15. Bayer AG Major Business
Table 16. Bayer AG Scleroderma Diagnostics and Therapeutics Product and Solutions
Table 17. Bayer AG Scleroderma Diagnostics and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Cytori Therapeutics, Inc. Corporate Information, Head Office, and Major Competitors
Table 19. Cytori Therapeutics, Inc. Major Business
Table 20. Cytori Therapeutics, Inc. Scleroderma Diagnostics and Therapeutics Product and Solutions
Table 21. Cytori Therapeutics, Inc. Scleroderma Diagnostics and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Cumberland Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors
Table 23. Cumberland Pharmaceuticals Inc Major Business
Table 24. Cumberland Pharmaceuticals Inc Scleroderma Diagnostics and Therapeutics Product and Solutions
Table 25. Cumberland Pharmaceuticals Inc Scleroderma Diagnostics and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Gilead Sciences, Inc. Corporate Information, Head Office, and Major Competitors
Table 27. Gilead Sciences, Inc. Major Business
Table 28. Gilead Sciences, Inc. Scleroderma Diagnostics and Therapeutics Product and Solutions
Table 29. Gilead Sciences, Inc. Scleroderma Diagnostics and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Pfizer, Inc. Corporate Information, Head Office, and Major Competitors
Table 31. Pfizer, Inc. Major Business
Table 32. Pfizer, Inc. Scleroderma Diagnostics and Therapeutics Product and Solutions
Table 33. Pfizer, Inc. Scleroderma Diagnostics and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Sanofi Corporate Information, Head Office, and Major Competitors
Table 35. Sanofi Major Business
Table 36. Sanofi Scleroderma Diagnostics and Therapeutics Product and Solutions
Table 37. Sanofi Scleroderma Diagnostics and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Corbus Pharmaceutical Holdings, Inc. Corporate Information, Head Office, and Major Competitors
Table 39. Corbus Pharmaceutical Holdings, Inc. Major Business
Table 40. Corbus Pharmaceutical Holdings, Inc. Scleroderma Diagnostics and Therapeutics Product and Solutions
Table 41. Corbus Pharmaceutical Holdings, Inc. Scleroderma Diagnostics and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. F. Hoffmann La Roche Ltd. Corporate Information, Head Office, and Major Competitors
Table 43. F. Hoffmann La Roche Ltd. Major Business
Table 44. F. Hoffmann La Roche Ltd. Scleroderma Diagnostics and Therapeutics Product and Solutions
Table 45. F. Hoffmann La Roche Ltd. Scleroderma Diagnostics and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Merck KGaA Corporate Information, Head Office, and Major Competitors
Table 47. Merck KGaA Major Business
Table 48. Merck KGaA Scleroderma Diagnostics and Therapeutics Product and Solutions
Table 49. Merck KGaA Scleroderma Diagnostics and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Global Scleroderma Diagnostics and Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 51. Global Scleroderma Diagnostics and Therapeutics Revenue Share by Players (2019-2021)
Table 52. Breakdown of Scleroderma Diagnostics and Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 53. Scleroderma Diagnostics and Therapeutics Players Head Office, Products and Services Provided
Table 54. Scleroderma Diagnostics and Therapeutics Mergers & Acquisitions in the Past Five Years
Table 55. Scleroderma Diagnostics and Therapeutics New Entrants and Expansion Plans
Table 56. Global Scleroderma Diagnostics and Therapeutics Revenue (USD Million) by Type (2016-2021)
Table 57. Global Scleroderma Diagnostics and Therapeutics Revenue Share by Type (2016-2021)
Table 58. Global Scleroderma Diagnostics and Therapeutics Revenue Forecast by Type (2021-2026)
Table 59. Global Scleroderma Diagnostics and Therapeutics Revenue by Application (2016-2021)
Table 60. Global Scleroderma Diagnostics and Therapeutics Revenue Forecast by Application (2021-2026)
Table 61. North America Scleroderma Diagnostics and Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 62. North America Scleroderma Diagnostics and Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 63. North America Scleroderma Diagnostics and Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 64. North America Scleroderma Diagnostics and Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 65. North America Scleroderma Diagnostics and Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 66. North America Scleroderma Diagnostics and Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 67. Europe Scleroderma Diagnostics and Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 68. Europe Scleroderma Diagnostics and Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 69. Europe Scleroderma Diagnostics and Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 70. Europe Scleroderma Diagnostics and Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 71. Europe Scleroderma Diagnostics and Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 72. Europe Scleroderma Diagnostics and Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 73. Asia-Pacific Scleroderma Diagnostics and Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 74. Asia-Pacific Scleroderma Diagnostics and Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 75. Asia-Pacific Scleroderma Diagnostics and Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 76. Asia-Pacific Scleroderma Diagnostics and Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 77. Asia-Pacific Scleroderma Diagnostics and Therapeutics Revenue by Region (2016-2021) & (USD Million)
Table 78. Asia-Pacific Scleroderma Diagnostics and Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 79. South America Scleroderma Diagnostics and Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 80. South America Scleroderma Diagnostics and Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 81. South America Scleroderma Diagnostics and Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 82. South America Scleroderma Diagnostics and Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 83. South America Scleroderma Diagnostics and Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 84. South America Scleroderma Diagnostics and Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 85. Middle East & Africa Scleroderma Diagnostics and Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 86. Middle East & Africa Scleroderma Diagnostics and Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 87. Middle East & Africa Scleroderma Diagnostics and Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 88. Middle East & Africa Scleroderma Diagnostics and Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 89. Middle East & Africa Scleroderma Diagnostics and Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 90. Middle East & Africa Scleroderma Diagnostics and Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Scleroderma Diagnostics and Therapeutics Picture
Figure 2. Global Scleroderma Diagnostics and Therapeutics Revenue Market Share by Type in 2020
Figure 3. Corticosteroids
Figure 4. Immunosuppressive Agents
Figure 5. Endothelin Receptor Agonists
Figure 6. Calcium Channel Blockers
Figure 7. PDE-5 Inhibitors
Figure 8. Chelating Agents
Figure 9. Prostacyclin Analogues
Figure 10. Others (H2 Blockers, Proton Pump Inhibitors, ACE Inhibitors etc.)
Figure 11. Scleroderma Diagnostics and Therapeutics Revenue Market Share by Application in 2020
Figure 12. Skin Biopsy Picture
Figure 13. Imaging Techniques Picture
Figure 14. Blood Tests Picture
Figure 15. Electrocardiogram and Echocardiogram Picture
Figure 16. Pulmonary Function Tests Picture
Figure 17. Global Scleroderma Diagnostics and Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 18. Global Scleroderma Diagnostics and Therapeutics Revenue and Forecast (2016-2026) & (USD Million)
Figure 19. Global Scleroderma Diagnostics and Therapeutics Revenue Market Share by Region (2016-2026)
Figure 20. Global Scleroderma Diagnostics and Therapeutics Revenue Market Share by Region in 2020
Figure 21. North America Scleroderma Diagnostics and Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. Europe Scleroderma Diagnostics and Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 23. Asia-Pacific Scleroderma Diagnostics and Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 24. South America Scleroderma Diagnostics and Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 25. Scleroderma Diagnostics and Therapeutics Market Drivers
Figure 26. Scleroderma Diagnostics and Therapeutics Market Restraints
Figure 27. Scleroderma Diagnostics and Therapeutics Market Trends
Figure 28. Actelion Pharmaceuticals, Inc. Recent Developments and Future Plans
Figure 29. Boehringer Ingelheim Recent Developments and Future Plans
Figure 30. Bayer AG Recent Developments and Future Plans
Figure 31. Cytori Therapeutics, Inc. Recent Developments and Future Plans
Figure 32. Cumberland Pharmaceuticals Inc Recent Developments and Future Plans
Figure 33. Gilead Sciences, Inc. Recent Developments and Future Plans
Figure 34. Pfizer, Inc. Recent Developments and Future Plans
Figure 35. Sanofi Recent Developments and Future Plans
Figure 36. Corbus Pharmaceutical Holdings, Inc. Recent Developments and Future Plans
Figure 37. F. Hoffmann La Roche Ltd. Recent Developments and Future Plans
Figure 38. Merck KGaA Recent Developments and Future Plans
Figure 40. Global Scleroderma Diagnostics and Therapeutics Revenue Share by Players in 2020
Figure 41. Scleroderma Diagnostics and Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 42. Global Top 3 Players Scleroderma Diagnostics and Therapeutics Revenue Market Share in 2020
Figure 43. Global Top 10 Players Scleroderma Diagnostics and Therapeutics Revenue Market Share in 2020
Figure 44. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 45. Global Scleroderma Diagnostics and Therapeutics Revenue Share by Type in 2020
Figure 46. Global Scleroderma Diagnostics and Therapeutics Market Share Forecast by Type (2021-2026)
Figure 47. Global Scleroderma Diagnostics and Therapeutics Revenue Share by Application in 2020
Figure 48. Global Scleroderma Diagnostics and Therapeutics Market Share Forecast by Application (2021-2026)
Figure 49. North America Scleroderma Diagnostics and Therapeutics Sales Market Share by Type (2016-2026)
Figure 50. North America Scleroderma Diagnostics and Therapeutics Sales Market Share by Application (2016-2026)
Figure 51. North America Scleroderma Diagnostics and Therapeutics Revenue Market Share by Country (2016-2026)
Figure 52. United States Scleroderma Diagnostics and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Canada Scleroderma Diagnostics and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Mexico Scleroderma Diagnostics and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Europe Scleroderma Diagnostics and Therapeutics Sales Market Share by Type (2016-2026)
Figure 56. Europe Scleroderma Diagnostics and Therapeutics Sales Market Share by Application (2016-2026)
Figure 57. Europe Scleroderma Diagnostics and Therapeutics Revenue Market Share by Country (2016-2026)
Figure 58. Germany Scleroderma Diagnostics and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. France Scleroderma Diagnostics and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. United Kingdom Scleroderma Diagnostics and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Russia Scleroderma Diagnostics and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Italy Scleroderma Diagnostics and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Asia-Pacific Scleroderma Diagnostics and Therapeutics Sales Market Share by Type (2016-2026)
Figure 64. Asia-Pacific Scleroderma Diagnostics and Therapeutics Sales Market Share by Application (2016-2026)
Figure 65. Asia-Pacific Scleroderma Diagnostics and Therapeutics Revenue Market Share by Region (2016-2026)
Figure 66. China Scleroderma Diagnostics and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Japan Scleroderma Diagnostics and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. South Korea Scleroderma Diagnostics and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. India Scleroderma Diagnostics and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Southeast Asia Scleroderma Diagnostics and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Australia Scleroderma Diagnostics and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. South America Scleroderma Diagnostics and Therapeutics Sales Market Share by Type (2016-2026)
Figure 73. South America Scleroderma Diagnostics and Therapeutics Sales Market Share by Application (2016-2026)
Figure 74. South America Scleroderma Diagnostics and Therapeutics Revenue Market Share by Country (2016-2026)
Figure 75. Brazil Scleroderma Diagnostics and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Argentina Scleroderma Diagnostics and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Middle East and Africa Scleroderma Diagnostics and Therapeutics Sales Market Share by Type (2016-2026)
Figure 78. Middle East and Africa Scleroderma Diagnostics and Therapeutics Sales Market Share by Application (2016-2026)
Figure 79. Middle East and Africa Scleroderma Diagnostics and Therapeutics Revenue Market Share by Country (2016-2026)
Figure 80. Turkey Scleroderma Diagnostics and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. Saudi Arabia Scleroderma Diagnostics and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 82. UAE Scleroderma Diagnostics and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 83. Methodology
Figure 84. Research Process and Data Source
世界の強皮症診断・治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Scleroderma Diagnostics and Therapeutics Market The global Scleroderma Diagnostics and Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analys…- 世界の強皮症治療薬市場規模・現状・予測（2021年-2027年） Scleroderma is a umbrella term for a group of autoimmune diseases resulting in changes in blood vessels, skin, muscles, and other organs. The symptoms of Scleroderma include thickened and stiff skin, lethargy, and poor blood flow to extremities of the limbs such as fingers and toes on exposure to co…
- 世界の胃腸治療・診断市場 2021：企業別、地域別、種類・用途別 The Gastrointestinal Therapeutics and Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optim…
- 世界のアルツハイマー病治療・診断市場規模・現状・予測（2021年-2027年） Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer’s disease worldwide emphasizing the necessity for developing an effective treatment. According to Alzheimer’s Association, in 2…
- 世界の脳卒中診断＆治療市場規模・現状・予測（2021年-2027年） Stroke refers to the brain attack. Stroke occurs when the supply of blood to the brain is either interrupted or reduced. Increasing number of mergers and acquisitions, rapid product launches, and rise in number of collaborations and partnerships are some of the latest trends that have been observed …